(精编)【医学课件】 Hormone therapy for metastatic breast cancer in 2016教学课件.pptVIP

Angelo Di Leo;;Recommendations from the American Society of Clinical Oncology;Recommendations from the ESO-ESMO ABC-2 panel;Primary endpoint: progression-free survival;1.0;0.1;Overall survival: first (50% events) and final (75% events) analyses ;Summary of patients who had at least one SAE during the whole treatment period (main trial plus follow-up phase);SAEs with outcome of death duringthe whole treatment period ;Previous data from phase II randomised studies testing Fulvestrant 500 mg: the FIRST trial;Updated TTP data from phase II randomized studies testing Fulvestrant 500 mg: the FIRST trial;;;Cooperation between ER and Cyclic D1 pathways enhances proliferation in luminal breast cancer;;;;;;;;;PALOMA-3: Study design;PALOMA-3: Updated investigator-assessed PFS (ITT);PALOMA-3: PFS by menopausal status;PALOMA-3 final analysis: Treatment effect by PIK3CA status;An attempt to move recent trial results into clinical practice;A functional Rb signature;Functional RBsig discriminates sensitive vs resistant BC cell lines;RBsig is prognostic in patients with ER+ tumors;ESR1 mutations and response to Palbociclib in the PALOMA 3 trial;ESR1 mutations and response to different endocrine therapy agents. The SOFEA trial results;Clinical trials comparing HT vs. HT + biological agent in ER+ advanced disease.  Focus on:- The BOLERO-2 trial;;PFS (based on local assessment at 18 mos. follow-up) and OS;Safety profile everolimus:most common adverse events;The TAMRAD trial;The TAMRAD trial: TTP results by level of response to prior aromatase inhibitor therapy;An attempt to move recent trial results into clinical practice;New agents currently tested in Phase III trials;;;;;Combined LEE011, Fulvestrant and PI3K Inhibition in ER+ Breast Cancer;Drug;The FERGI trial: a phase II randomised trial;Krop I et al, Lancet Oncol, 17(6):811-21, 2016;Potential (non-mutually exclusive) expl